

Bioblast Pharma Ltd.  
Form 6-K  
January 18, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: January 2017

Commission file number: 001-36578

BIOBLAST PHARMA LTD.

(Translation of registrant's name into English)

37 Dereh Menechem Begin St., 15<sup>th</sup> Floor

Tel Aviv 6522042 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Edgar Filing: Bioblast Pharma Ltd. - Form 6-K

Form 20-F x Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): \_\_\_\_\_

**CONTENTS**

This Report of Foreign Private Issuer on Form 6-K of the Registrant consists of the press release issued by the Registrant on January 18, 2017, announcing Phase 2a results of trehalose in patients with Spinocerebellar Ataxia Type 3 (SCA3), which is attached hereto as Exhibit 99.1.

The first five paragraphs and the section titled “Forward Looking Statements” in the press release are incorporated by reference into the registration statement on Form F-3 (File No. 333-206032) and the registration statements on Form S-8 (File No. 333-203114 and File No. 210459) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**Exhibit No.**

99.1 Press Release issued by Bioblast Pharma Ltd. on January 18, 2017, announcing Phase 2a results of trehalose in patients with SCA3.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bioblast Pharma Ltd.  
(Registrant)

By: /s/ Chaime Orlev  
Name: Chaime Orlev  
Title: Chief Financial Officer, Vice President of Finance and Administration

Date: January 18, 2017